Alkermes Announces Webcast of R&D Day on July 17, 2013
DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NAS: ALKS) announced today that it will webcast its Research and Development (R&D) Day presentation on Wednesday, July 17, 2013. The webcast will begin at 1:00 p.m. EDT (6:00 p.m. BST). At the meeting, members of Alkermes' senior management will provide detailed information on the company's lead clinical programs, discuss its distinctive R&D strategy and introduce new product candidates.
A live webcast of the event will be available on the Investors tab of the company's website at www.alkermes.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start. This webcast will be archived on Alkermes' website for one month.
Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Eva Stroynowski, +1 781-609-6823
KEYWORDS: United Kingdom United States Europe North America Massachusetts Ireland
The article Alkermes Announces Webcast of R&D Day on July 17, 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.